Abstract
Background: The purpose of this study was to clarify the alterations of major immune regulators in peripheral blood mononuclear cells (PBMCs) of cancer patients and to analyze the association with the disease progression in breast cancer patients. Methods: The study included 6 healthy volunteers (HVs), 12 primary breast cancer (PBC) patients, and 30 metastatic breast cancer (MBC) patients. The expression of immune regulators such as, CCR6, CD4, CD8, CD14, CD40, CD56, CD80, CTLA4, CXCR4, FOXP3, IDO-1, IDO-2, NKG2D, NRP-1, PD-1, and PD-L1 mRNA in PBMCs was measured by quantitative RT-PCR. Analysis of variance with contrasts was performed to find expression patterns of the three groups (HVs, PBC, MBC). Results: We clarified the alterations of mRNA of major immune regulators PD-L1, FOXP3, CD80, CD40, and CD14 in PBMCs of cancer patients and the association of these alternations with disease progression. Furthermore, PD-L1 expression was correlated with serum interferon-γ production. Conclusion: Our data suggested that mRNA expressions of PD-L1, FOXP3, CD80, CD40 and CD14 in PBMCs are affected by disease progression. Understanding the roles of these various interactions will be of importance to future studies aiming to uncover biomarkers for predicting response to immune therapy.
| Original language | English |
|---|---|
| Pages (from-to) | 111-120 |
| Number of pages | 10 |
| Journal | Breast Cancer |
| Volume | 24 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - Jan 1 2017 |
| Externally published | Yes |
Fingerprint
Keywords
- Breast cancer
- CD40 and PBMCs
- CD80
- PD-1
- PD-L1
ASJC Scopus subject areas
- Oncology
- Radiology Nuclear Medicine and imaging
- Pharmacology (medical)
Cite this
Altered expression of major immune regulatory molecules in peripheral blood immune cells associated with breast cancer. / Kawaguchi, Kosuke; Suzuki, Eiji; Yamaguchi, Ayane; Yamamoto, Michio; Morita, Satoshi; Toi, Masakazu.
In: Breast Cancer, Vol. 24, No. 1, 01.01.2017, p. 111-120.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Altered expression of major immune regulatory molecules in peripheral blood immune cells associated with breast cancer
AU - Kawaguchi, Kosuke
AU - Suzuki, Eiji
AU - Yamaguchi, Ayane
AU - Yamamoto, Michio
AU - Morita, Satoshi
AU - Toi, Masakazu
PY - 2017/1/1
Y1 - 2017/1/1
N2 - Background: The purpose of this study was to clarify the alterations of major immune regulators in peripheral blood mononuclear cells (PBMCs) of cancer patients and to analyze the association with the disease progression in breast cancer patients. Methods: The study included 6 healthy volunteers (HVs), 12 primary breast cancer (PBC) patients, and 30 metastatic breast cancer (MBC) patients. The expression of immune regulators such as, CCR6, CD4, CD8, CD14, CD40, CD56, CD80, CTLA4, CXCR4, FOXP3, IDO-1, IDO-2, NKG2D, NRP-1, PD-1, and PD-L1 mRNA in PBMCs was measured by quantitative RT-PCR. Analysis of variance with contrasts was performed to find expression patterns of the three groups (HVs, PBC, MBC). Results: We clarified the alterations of mRNA of major immune regulators PD-L1, FOXP3, CD80, CD40, and CD14 in PBMCs of cancer patients and the association of these alternations with disease progression. Furthermore, PD-L1 expression was correlated with serum interferon-γ production. Conclusion: Our data suggested that mRNA expressions of PD-L1, FOXP3, CD80, CD40 and CD14 in PBMCs are affected by disease progression. Understanding the roles of these various interactions will be of importance to future studies aiming to uncover biomarkers for predicting response to immune therapy.
AB - Background: The purpose of this study was to clarify the alterations of major immune regulators in peripheral blood mononuclear cells (PBMCs) of cancer patients and to analyze the association with the disease progression in breast cancer patients. Methods: The study included 6 healthy volunteers (HVs), 12 primary breast cancer (PBC) patients, and 30 metastatic breast cancer (MBC) patients. The expression of immune regulators such as, CCR6, CD4, CD8, CD14, CD40, CD56, CD80, CTLA4, CXCR4, FOXP3, IDO-1, IDO-2, NKG2D, NRP-1, PD-1, and PD-L1 mRNA in PBMCs was measured by quantitative RT-PCR. Analysis of variance with contrasts was performed to find expression patterns of the three groups (HVs, PBC, MBC). Results: We clarified the alterations of mRNA of major immune regulators PD-L1, FOXP3, CD80, CD40, and CD14 in PBMCs of cancer patients and the association of these alternations with disease progression. Furthermore, PD-L1 expression was correlated with serum interferon-γ production. Conclusion: Our data suggested that mRNA expressions of PD-L1, FOXP3, CD80, CD40 and CD14 in PBMCs are affected by disease progression. Understanding the roles of these various interactions will be of importance to future studies aiming to uncover biomarkers for predicting response to immune therapy.
KW - Breast cancer
KW - CD40 and PBMCs
KW - CD80
KW - PD-1
KW - PD-L1
UR - http://www.scopus.com/inward/record.url?scp=84960119588&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84960119588&partnerID=8YFLogxK
U2 - 10.1007/s12282-016-0682-7
DO - 10.1007/s12282-016-0682-7
M3 - Article
C2 - 26942414
AN - SCOPUS:84960119588
VL - 24
SP - 111
EP - 120
JO - Breast Cancer
JF - Breast Cancer
SN - 1340-6868
IS - 1
ER -